The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesis is that obstructive sleep apnea (OSA) patients with a low arousal threshold may wake up too early during a respiratory event, before upper airway muscles can be activated to achieve stable ventilation. Thus, strategies to manipulate the respiratory arousal threshold could potentially improve the quality of sleep and sleep disordered breathing. Agents that raise arousal threshold are therefore likely to benefit some patients with OSA. The overall goal of this project is to determine the importance of the arousal threshold in OSA, determine which patients might benefit from a raised arousal threshold, and test this hypothesis by using pharmacological manipulation of the arousal threshold to achieve this goal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea

NCT04639193

OSA Obstructive Sleep Apnea

COMPLETED PHASE2

Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

NCT06295562

Obstructive Sleep Apnea of Adult

COMPLETED PHASE4

Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B

NCT02436031

Sleep Apnea, Obstructive

COMPLETED PHASE2

The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation

NCT03506906

Hypoventilation Syndrome Chronic Obstructive Pulmonary Disease Obesity Hypoventilation Syndrome +2 more

COMPLETED NA

Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea

NCT03892772

Sleep Apnea

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized double-blinded crossover pilot study. The investigators will test whether Venlafaxine has important effects on the apnea hypopnea index. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) for the treatment of depression and anxiety. Venlafaxine increases serum serotonin level, which may affect arousal threshold. Furthermore, higher serotonin level theoretically may improve muscle tone, including upper airway muscle. Therefore, the investigators hypothesize that venlafaxine may decrease arousal threshold and improve muscle tone, leading to improvement of OSA.

Eligible participants will undergo overnight polysomonography as described below and will receive either Venlafaxine(50 mg 2 hour prior to sleep) or placebo (in random order) followed roughly 7 days later with placebo or donepezil. This aim will allow us to test the impact of Venlafaxine on the apnea hypopnea index.

The change in apnea hypopnea index will be compared in the Venlafaxine groups with the placebo group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Venlafaxine

50mg of Venlafaxine before sleep

Group Type ACTIVE_COMPARATOR

Venlafaxine

Intervention Type DRUG

Venlafaxine 50mg before sleep

Placebo

One piece of placebo before sleep

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

One piece of placebo before sleep

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venlafaxine

Venlafaxine 50mg before sleep

Intervention Type DRUG

Placebo

One piece of placebo before sleep

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18-70 years
* sleep study (with apnea hypopnea index\>5)
* Diagnosis of obstructive sleep apnea

Exclusion Criteria

* Any known cardiac (apart from treated hypertension), pulmonary (including uncontrolled asthma), renal, neurologic (including epilepsy), neuromuscular, or hepatic disease.
* Susceptible to stomach ulcers.
* co-administration of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing the MAO inhibitor); initiation of MAO inhibitor intended to treat psychiatric disorders within 7 days of discontinuing venlafaxine; initiation in patients receiving linezolid or intravenous methylene blue
* Pregnant women.
* History of hypersensitivity to Afrin, Lidocaine (all Aims) or venlafaxine
* History of bleeding diathesis and/or gastrointestinal bleeding.
* Glaucoma and Urinary Retention
* Use of any medications that may affect sleep or breathing.
* Use of any medications that have known interaction with venlafaxine and the interaction may significantly increase the risk of the subject or decrease the therapeutic effect of the medication.
* A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.
* Substantial cigarette (\>5/day), alcohol (\>3oz/day) or use of illicit drugs.
* More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.
* Desaturations to below 70% lasting greater than 10 seconds in duration per event

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No